# Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation

Study · id `cardio:ct-nct05955365` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05955365](<https://clinicaltrials.gov/study/NCT05955365>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05955365

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3010 participants.

## Technical summary

Registry record NCT05955365. Randomized; no masking; primary purpose treatment. Start 2023-12-18 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3010 participants (planned count; ClinicalTrials.gov record NCT05955365, source copy `cardio:ctgov-nct05955365-2026-11-16`, retrieved 2026-11-18)
- Started: 2023-12-18 (actual) (ClinicalTrials.gov record NCT05955365, source copy `cardio:ctgov-nct05955365-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT05955365, source copy `cardio:ctgov-nct05955365-2026-11-16`, retrieved 2026-11-18)
- Completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT05955365, source copy `cardio:ctgov-nct05955365-2026-11-16`, retrieved 2026-11-18)
- Countries: Belgium; France; Germany; Italy; Netherlands; Poland; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT05955365, source copy `cardio:ctgov-nct05955365-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05955365-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation
- Acronym: MATRIX-2
- Condition: Percutaneous Coronary Intervention (PCI)
- Condition: Atrial Fibrillation (AF)
- Condition: Oral Anticoagulation
- Condition: P2Y12 Inhibitor
- Intervention (Drug): P2Y12 inhibitor
- Intervention (Drug): Aspirin
- Intervention (Drug): DOAC
- Lead sponsor: Insel Gruppe AG, University Hospital Bern
- Lead sponsor class: OTHER
- Collaborator: Sahajanand Medical Technologies Limited
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Insel Gruppe AG, University Hospital Bern (`cardio:org-insel-gruppe-ag-university-hospital-bern`)

## Provenance

Content hash: cf1873d63c2b9ad411f5ed54aed5103f9a1b1d721ee635e43f5ce098c35767ca
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
